我院非瓣膜性房颤患者抗凝治疗现状调查分析  

Investigation and Analysis of the Anticoagulant Therapy for Patients with Non-valvular Atrial Fibrillation in Our Hospital

作　　者：王长江[1] 费爱丽[1] 朱航[1] 王小琴[1] 涂厉标[1] WANG Changjiang;FEI Aili;ZHU Hang;WANG Xiaoqin;TU Libiao(Dept. of Pharmacy,Jiaxing Second Hospital,Zhejiang Jiaxing 314000,China)

机构地区：[1]嘉兴市第二医院药学部,浙江嘉兴314000

出　　处：《中国药房》2017年第11期1459-1462,共4页China Pharmacy

基　　金：浙江省药学会医院药学专项科研资助项目(No.2013ZYY16);嘉兴市科技计划项目(No.2015C23017)

摘　　要：目的:了解非瓣膜性心房颤动患者抗凝治疗现状,为其规范化抗凝治疗提供参考。方法:选取我院2015年7月-2016年6月非瓣膜性心房颤动患者1 056例,按照《2012年欧洲心脏病学会(ESC)心房颤动治疗指南》,对患者进行血栓栓塞危险和出血风险评估,并评价其抗凝治疗规范化情况。结果:血栓栓塞危险评分≥1的例数为1 028例,占总非瓣膜性心房颤动患者的97.3%。763例患者接受抗血栓治疗,而服用华法林抗凝治疗的仅有139例。服用华法林患者出院前凝血酶原时间的国际标准化比值达标率仅30.9%。结论:非瓣膜性心房颤动患者抗凝治疗现状不容乐观,应采取有效的干预措施,提高心房颤动患者抗凝治疗规范化程度。OBJECTIVE:To investigate the current situation of anticoagulant therapy for patients with non-valvular atrial fibrillation,and to provide reference for standardized anticoagulant therapy.METHODS:A total of1056patients with non-valvular atrial fibrillation were collected from our hospital during Jul.2015-Jun.2016.According to2012European Society of Cardiology Guidelines for the Management of Atrial Fibrillation,the risks of thrombosis and hemorrhage were evaluated,and the standardized anticoagulant therapy was also evaluated.RESULTS:Among1056patients with non-valvular atrial fibrillation,the number of patients with thrombosis risk score≥1was1028,accounting for97.3%.763patients received antithrombosis therapy,and only139patients were given warfarin anticoagulant therapy.The international normalized ratio(INR)of prothrombin time in just30.9%of patients receiving warfarin was in line with the standard before discharge.CONCLUSIONS:The anticoagulant therapy for patients with non-valvular atrial fibrillation is still not optimistic,and effective measure should be adopted to improve the standardization of anticoagulant therapy in the patients with atrial fibrillation.

关 键 词：非瓣膜性心房颤动 华法林 抗凝 调查 

分 类 号：R969.3[医药卫生—药理学]